This content is machine translated Advanced hormone-sensitive prostate cancer Sustained testosterone reduction without injections Since January 1, 2024, the oral GnRH antagonist Relugolix has been approved in Switzerland for the treatment of adults with advanced hormone-sensitive prostate cancer [1, 2]. This gives patients access…
View Post 4 min This content is machine translated Urooncology From diagnosis to therapy: Urological tumors in focus Annually, the American Society of Clinical Oncology Congress addresses the current state of research on urogenital tumors. The latest study results regarding diagnosis and therapy of prostate cancer, renal cell…
View Post 10 min This content is machine translated Prostate Cancer PSMA in diagnostics and therapy: Where is the journey leading? The prostate specific membrane antigen (PSMA) plays an increasingly important role not only in the diagnosis of prostate carcinoma. The radioligand 117Lutetium-PSMA-617also provides a new therapeutic option in advanced castration-resistant…
View Post 8 min This content is machine translated News in metastatic prostate cancer. What impact will the studies published in 2020/2021 have on clinical practice? The years 2020 and 2021 have brought some novelties in metastatic prostate cancer. Thus, with 177Lutetium-PSMA-617and the PARP inhibitor Olaparib, two new active substances are available. The latter is already… CME-Test
View Post 4 min This content is machine translated Biomarkers and immunotherapy New horizons in advanced prostate cancer Metastatic castration-resistant prostate cancer (mCRPC) has been considered primarily the domain of novel hormone and taxane therapy. Increasingly, however, other treatment approaches are being tested with sometimes promising results. In…
View Post 6 min This content is machine translated News from the world of oncology The hottest studies at a glance Every year, ESMO presents the most relevant research results of its congress within the framework of so-called Presidential Symposia. Also at this year’s virtual execution, the presentation of those studies…
View Post 2 min This content is machine translated Prostate Cancer Prognostic marker early incontinence The treatment of choice for prostate cancer is radical prostatectomy. It is usually followed by incontinence. Attainment of early continence could serve as a reliable prognostic marker.
View Post 6 min This content is machine translated DGHO in Vienna Prostate and breast cancer: the future belongs to combined therapies Treatment options are often limited in both prostate and breast carcinoma. The search for new effective drugs and combination therapies is therefore the primary goal of current studies.
View Post 3 min This content is machine translated Annual Congress of the American Urological Association (AUA), San Francisco Risk assessment in prostate cancer: what do biomarkers do? Since the implementation of PSA testing, the number of PCa diagnoses has multiplied. Biomarkers are increasingly used to prevent overdiagnosis and overtreatment. New approaches, but also limitations, of microbiological testing…
View Post 6 min This content is machine translated 7th Interdisciplinary Prostate Cancer Symposium in St. Gallen Active surveillance in prostate cancer – when is this possible? Early detection of prostate cancer (PCa) was revolutionized with the introduction of PSA (prostate-specific antigen). Since its introduction, however, it has been noticed that a large number of men with…
View Post 8 min This content is machine translated ASCO 2017 in Chicago Groundbreaking on tumors of the prostate and gallbladder There was big news at the 2017 ASCO Congress. First, abiraterone is pushing into the first-line setting in metastatic prostate cancer. On the other hand, there is a new standard…
